Important safety information
What you should know before taking Saxenda.
Weight loss Rx online. See if you qualify
Safety info: Saxenda treats obesity or overweight (with weight-related problems), along with diet and exercise. Saxenda may have serious side effects, including possible thyroid tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC or MEN 2. Do not use if you are pregnant. Read more about serious warnings and safety info.
Which GLP-1 is right for you?
Semaglutide injection was first approved under the brand name Ozempic in 2017 as a treatment for type 2 diabetes. In 2021, the FDA approved the drug at a different dosage under the brand name Wegovy as a weight loss medication. Doctors often, using their medical judgment and discretion, prescribe both for weight loss. Liraglutide injection was FDA approved for weight loss in 2014 under the brand name Saxenda.
All three medications are GLP-1s, but there are some key differences between them.
Is using medication to lose weight cheating?
In four days
Typically in one week
In 1-3 weeks
“I started losing weight almost immediately. To me, truly, this has been a game-changer.”
Dr. Pepper Ro Ambassador who inspired the Body Program, after taking GLP-1 medication
“I have never felt better. I have never had more energy. This medication changed my life.”
Mary Ro Ambassador who inspired the Body Program, after taking GLP-1 medication
Meet our expert
From diagnosis to delivery, our healthcare providers are with patients every step of the way.
“I’ve had some pretty amazing success. I’m down 15 pounds and I couldn’t be happier."
“It's really helping handle my cravings better, which is what I really like about this program."
“It was like a switch once I started the medication, I just wasn’t so obsessed with food.”
14 min read
How much does Saxenda cost?
15 min read
Saxenda side effects
7 min read
7 min read
What are GLP-1 receptor agonists?
Saxenda is a brand-name version of the generic medication liraglutide. Saxenda is FDA-approved and clinically proven to help with weight loss and belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs limit your appetite by acting like a hormone that slows down your gut, making you feel less hungry. People on Saxenda lost an average of 9% of their body weight after one year.*
Saxenda works for weight loss by mimicking the hormone GLP-1, which reduces appetite and slows down the movement of food through your stomach. This may make you feel full longer and therefore eat less, which can lead to weight loss. When paired with healthy food choices and regular exercise, Saxenda can assist you in reaching and maintaining your long-term weight goals.
Yes. If appropriate, adults can get Saxenda (liraglutide) through the Body Program. Currently, the Body Program is only available for adults 18 years and older.
Yes, Saxenda is FDA approved for weight loss in adults with a BMI of ≥30 or a BMI of ≥27 and at least one weight-related condition, such as high blood pressure or high cholesterol. Saxenda is supposed to be taken in combination with a reduced-calorie diet and greater physical activity.
Saxenda is a clear liquid that comes in prefilled injection pens. Each pen contains multiple doses. If prescribed, you (or someone in your household) will administer the injection once daily under the skin of your stomach, thigh, or arm. You’ll also receive clear instructions on using the injection pen, and your Ro-affiliated provider can offer additional advice.
Like other GLP-1 medications like Ozempic and Wegovy (active ingredient semaglutide), dosing gradually increases with Saxenda. The typical Saxenda dosing schedule starts with 0.6 mg once daily for one week. After that, your dose will increase each week until you reach the max amount of 3 mg per day, also called the maintenance dose.
Non-diabetic patients who completed the 56-week clinical trial lost an average of 9% of their body weight.
*In a 56-week clinical trial of 3,731 non-diabetic patients with obesity (BMI ≥30) or with overweight (BMI ≥27) and at least one weight-related condition, the 1,812 patients that completed the trial lost an average of 9.2% of their body weight, when Saxenda was paired with a reduced-calorie diet and increased physical activity.